Rockefeller Capital Management L.P. Sells 100,923 Shares of LeMaitre Vascular, Inc. $LMAT

Rockefeller Capital Management L.P. lowered its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 37.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 165,556 shares of the medical instruments supplier’s stock after selling 100,923 shares during the period. Rockefeller Capital Management L.P.’s holdings in LeMaitre Vascular were worth $13,427,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of LMAT. Vanguard Group Inc. boosted its holdings in LeMaitre Vascular by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 1,622,033 shares of the medical instruments supplier’s stock valued at $131,547,000 after purchasing an additional 21,946 shares during the period. First Trust Advisors LP increased its holdings in shares of LeMaitre Vascular by 13.4% in the fourth quarter. First Trust Advisors LP now owns 940,140 shares of the medical instruments supplier’s stock worth $76,245,000 after purchasing an additional 111,193 shares during the period. State Street Corp raised its position in shares of LeMaitre Vascular by 0.8% in the fourth quarter. State Street Corp now owns 806,993 shares of the medical instruments supplier’s stock worth $65,447,000 after buying an additional 6,130 shares in the last quarter. Congress Asset Management Co. raised its position in shares of LeMaitre Vascular by 5.8% in the fourth quarter. Congress Asset Management Co. now owns 732,331 shares of the medical instruments supplier’s stock worth $59,392,000 after buying an additional 40,065 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in LeMaitre Vascular by 20.1% during the fourth quarter. Geode Capital Management LLC now owns 633,089 shares of the medical instruments supplier’s stock valued at $51,351,000 after buying an additional 105,921 shares during the period. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Stock Up 0.3%

LMAT opened at $92.25 on Thursday. The stock has a market cap of $2.11 billion, a PE ratio of 34.04, a P/E/G ratio of 2.55 and a beta of 0.54. The company has a quick ratio of 12.20, a current ratio of 14.32 and a debt-to-equity ratio of 0.42. LeMaitre Vascular, Inc. has a 52 week low of $79.00 and a 52 week high of $118.01. The business’s fifty day simple moving average is $101.02 and its 200 day simple moving average is $96.57.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.02. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The business had revenue of $66.55 million for the quarter, compared to the consensus estimate of $66.67 million. During the same quarter last year, the business posted $0.48 earnings per share. The company’s revenue for the quarter was up 11.1% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. As a group, research analysts expect that LeMaitre Vascular, Inc. will post 3 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Thursday, May 21st were given a $0.25 dividend. The ex-dividend date was Thursday, May 21st. This represents a $1.00 dividend on an annualized basis and a yield of 1.1%. LeMaitre Vascular’s payout ratio is presently 36.90%.

Insider Buying and Selling

In other LeMaitre Vascular news, Director Bridget A. Ross sold 5,044 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $111.10, for a total value of $560,388.40. Following the completion of the sale, the director owned 3,942 shares of the company’s stock, valued at $437,956.20. This represents a 56.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Trent G. Kamke sold 2,928 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $107.00, for a total value of $313,296.00. Following the completion of the sale, the insider directly owned 3,749 shares of the company’s stock, valued at approximately $401,143. This represents a 43.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 54,453 shares of company stock worth $5,906,174 in the last quarter. 7.40% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Roth Mkm restated a “buy” rating and set a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a research report on Thursday, February 26th. Wall Street Zen downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Freedom Capital raised LeMaitre Vascular to a “hold” rating in a report on Tuesday, March 31st. Wells Fargo & Company upped their price objective on shares of LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Finally, Zacks Research raised shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research note on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $112.60.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.